TickerStar monitors official filings, investor releases, earnings, and call updates for ICCM. Subscribe to ICCM alerts to receive concise, source-linked alerts when TickerStar detects a meaningful company update.
TickerStar filters routine noise and surfaces investor-relevant filings, releases, earnings, and call updates.
No actual results were disclosed, so the filing cannot be compared with the prior FY2026 guidance midpoint. At the adjourned Annual and Special General Meeting, shareholders approved the agenda items described in the October 5, 2026 proxy statement after a quorum was present. The filing does not provide proposal-level voting results.
Read source-backed briefIceCure Medical announced that the first patient in its ChoICE post-marketing study was treated with ProSense cryoablation at West Cancer Center & Research Institute in Germantown, Tennessee. The study is designed to enroll approximately 400 patients across up to 30 U.S. clinical sites and generate real-world data for ProSense's FDA-cleared breast cancer indication. The release contains no reported financial results or financial guidance; participating sites are expected to serve as both study centers and active...
Read source-backed briefIceCure Medical announced that the first two patients have been enrolled at two U.S. clinical sites in the post-marketing ChoICE Study evaluating ProSense cryoablation for local treatment of low-risk breast cancer. The first patient was enrolled at West Cancer Center & Research Institute in Germantown, Tennessee by Dr. Richard E. Fine, and the second at Adventist Health Glendale in Glendale, California under Dr. Dennis Holmes. The study is designed to enroll approximately 400 patients across up to 30 U.S. clinic...
Read source-backed brief